Peptide Ags presented by class I MHC molecules on human melanomas and that are recognized by CD8(+) T cells are the subjects of many studies of antitumor immunity and represent attractive candidates for therapeutic approaches. However, no direct quantitative measurements exist to reveal their expression hierarchy on the cell surface. Using novel recombinant Abs which bind these Ags with a peptide-specific, MHC-restricted manner, we demonstrate a defined pattern of expression hierarchy of peptide-HLA-A2 complexes derived from three major differentiation Ags: gp100, Melan-A/Mart-1, and tyrosinase. Studying melanoma cell lines derived from multiple patients, we reveal a surprisingly high level of presentation of tyrosinase-derived complexes an...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
International audienceHLA-A*0201 melanoma patients often develop a CTL response to an immunodominant...
Antigenic peptides derived from differentiation antigens of the melanocyte lineage were recently ide...
Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC cl...
The Melan-A/MART-1(26-35) antigenic peptide is one of the best studied human tumor-associated antige...
The human tyrosinase gene codes for two distinct antigens that are recognized by HLA-A*0201-restrict...
Antigenic peptides derived from several differentiation antigens of the melanocyte lineage were rece...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identifie...
Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identifie...
Abstract HLA-A2.1-associated peptides, extracted from human melanoma cells, were used to study epito...
© The Author(s) 2015. This article is published with open access at Springerlink.com and in vitro co...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
International audienceHLA-A*0201 melanoma patients often develop a CTL response to an immunodominant...
Antigenic peptides derived from differentiation antigens of the melanocyte lineage were recently ide...
Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC cl...
The Melan-A/MART-1(26-35) antigenic peptide is one of the best studied human tumor-associated antige...
The human tyrosinase gene codes for two distinct antigens that are recognized by HLA-A*0201-restrict...
Antigenic peptides derived from several differentiation antigens of the melanocyte lineage were rece...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
International audienceWe previously described HLA-B35-restricted melanoma tumor-infiltrating lymphoc...
Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identifie...
Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identifie...
Abstract HLA-A2.1-associated peptides, extracted from human melanoma cells, were used to study epito...
© The Author(s) 2015. This article is published with open access at Springerlink.com and in vitro co...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
HLA-A*0201 melanoma patients often develop a CTL response to an immunodominant peptide derived from ...
International audienceHLA-A*0201 melanoma patients often develop a CTL response to an immunodominant...